Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment Novo discontinued last October.
Novo Nordisk has handed over STEM-PD, an experimental stem-cell therapy for Parkinson’s disease, to Cellular Intelligence, an AI biotech backed by Mark Zuckerberg, the companies said on Monday.
Financial terms were not disclosed. Novo will take an equity stake in the startup and is eligible for future milestone payments and royalties. Novo discontinued the therapy last October when it shut down its cell-therapy unit during a broader restructuring.
STEM-PD is an allogeneic, stem-cell-derived treatment designed to replace dopamine-producing nerve cells lost in Parkinson’s disease. It had been in early clinical development at Novo before the unit was wound down.
Cellular Intelligence said it intends to use its proprietary AI platform to accelerate the programme, scale manufacturing and bring down production costs.
Cellular Intelligence has raised more than $60m to date from investors including Khosla Ventures and the Chan Zuckerberg Initiative, Zuckerberg and Priscilla Chan’s philanthropic vehicle.
The deal extends an investment pattern that has seen CZI commit substantial capital to AI-driven biology in recent months.
For Novo, the deal closes out one of the loose ends from last October’s restructuring, which prioritised the company’s obesity and diabetes franchises after demand for Wegovy and Ozempic continued to outpace supply.
The cell-therapy unit was an early-stage research operation rather than a commercial line; its discontinuation freed engineering and manufacturing capacity for GLP-1 production.
Last week Novo reported that Wegovy held 65% of new US prescriptions and that obesity-care sales rose 22% on a constant-currency basis.
For Cellular Intelligence, the deal gives the company a clinical-stage asset to anchor its AI-platform pitch. STEM-PD is well-characterised; Novo’s prior investment took it through the preclinical and early-clinical stages.
The startup’s case to investors will now combine an in-development therapy with the cost-and-speed claims its AI platform is built around.
There is no disclosed timeline for the next clinical milestone. Cellular Intelligence has not said when it expects to file an IND amendment or what dose-finding work it will pick up from Novo’s earlier programme.
Parkinson’s affects around 10 million people worldwide. Treatments that replace lost dopamine-producing cells have been pursued by multiple research groups for decades; Cellular Intelligence’s bet is that AI-assisted manufacturing and dose selection can make a treatment of this kind commercially viable on a timeline conventional cell-therapy programmes have not been able to match.
The companies did not say whether Novo’s equity stake gives it observer rights, IP back-licensing or any operational role at Cellular Intelligence. The deal closes immediately.
